Cargando…

JAK/STAT signaling in hepatocellular carcinoma

Liver cancer is the second most lethal cancer in the world with limited treatment options. Hepatocellular carcinoma (HCC), which accounts for more than 80% of all liver cancers, has had increasing global incidence over the past few years. There is an urgent need for novel and better therapeutic inte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hin Tang, Justin Jit, Hao Thng, Dexter Kai, Lim, Jhin Jieh, Toh, Tan Boon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7137178/ https://www.ncbi.nlm.nih.gov/pubmed/32273976 http://dx.doi.org/10.2217/hep-2020-0001

Ejemplares similares

Epigenetics of hepatocellular carcinoma
por: Toh, Tan Boon, et al.
Publicado: (2019)

Eph receptor B2 (EPHB2) regulates cancer stem cell-like properties in hepatocellular carcinoma
por: Lim, Jhin Jieh, et al.
Publicado: (2022)

Epigenetics in cancer stem cells
por: Toh, Tan Boon, et al.
Publicado: (2017)

Jak-Stat Signaling Induced by Interleukin-6 Family Cytokines in Hepatocellular Carcinoma
por: Lokau, Juliane, et al.
Publicado: (2019)

Exploring the JAK/STAT Signaling Pathway in Hepatocellular Carcinoma: Unraveling Signaling Complexity and Therapeutic Implications
por: Park, Hyunjung, et al.
Publicado: (2023)

Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors
por: Lim, Jhin Jieh, et al.
Publicado: (2022)

Activating JAK1 mutation may predict the sensitivity of JAK-STAT inhibition in hepatocellular carcinoma
por: Yang, Shuqun, et al.
Publicado: (2015)

Targeted Inhibition of Purine Metabolism Is Effective in Suppressing Hepatocellular Carcinoma Progression
por: Chong, Yong Chun, et al.
Publicado: (2020)

Splice‐switch oligonucleotide‐based combinatorial platform prioritizes synthetic lethal targets CHK1 and BRD4 against MYC‐driven hepatocellular carcinoma
por: Thng, Dexter Kai Hao, et al.
Publicado: (2022)

JAK-STAT signaling and myocardial glucose metabolism
por: Frias, Miguel A, et al.
Publicado: (2013)

The role of JAK-STAT signaling within the CNS
por: Nicolas, Celine S., et al.
Publicado: (2013)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

A review of JAK–STAT signalling in the pathogenesis of spondyloarthritis and the role of JAK inhibition
por: McInnes, Iain B, et al.
Publicado: (2021)

JAK-STAT signaling in cardiomyogenesis of cardiac stem cells
por: Mohri, Tomomi, et al.
Publicado: (2012)

Targeting the tumor microenvironment: JAK-STAT3 signaling
por: Bournazou, Eirini, et al.
Publicado: (2013)

Leptin-Induced JAK/STAT Signaling and Cancer Growth
por: Mullen, McKay, et al.
Publicado: (2016)

The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma
por: Ou, Alexander, et al.
Publicado: (2021)

CKS1B promotes the progression of hepatocellular carcinoma by activating JAK/STAT3 signal pathway
por: Liu, Xitao, et al.
Publicado: (2021)

Histone‐lysine N‐methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc‐driven liver cancer
por: Thng, Dexter Kai Hao, et al.
Publicado: (2023)

Dihydrotanshinone Inhibits Hepatocellular Carcinoma by Suppressing the JAK2/STAT3 Pathway
por: Hu, Xue, et al.
Publicado: (2021)

Myeloproliferative neoplasms and the JAK/STAT signaling pathway: an overview
por: de Freitas, Renata Mendes, et al.
Publicado: (2015)

The JAK/STAT signaling pathway: from bench to clinic
por: Hu, Xiaoyi, et al.
Publicado: (2021)

Potential Role of JAK-STAT Signaling Pathway in the Neurogenic-to-Gliogenic Shift in Down Syndrome Brain
por: Lee, Han-Chung, et al.
Publicado: (2016)

JAK-STAT Signalling Pathway in Cancer
por: Brooks, Andrew J., et al.
Publicado: (2020)

JAK-STAT3 and somatic cell reprogramming
por: Tang, Yong, et al.
Publicado: (2013)

EYA2 suppresses the progression of hepatocellular carcinoma via SOCS3-mediated blockade of JAK/STAT signaling
por: Liu, Ze-Kun, et al.
Publicado: (2021)

Computational models of the JAK1/2-STAT1 signaling
por: Gambin, Anna, et al.
Publicado: (2013)

Negative Regulators of JAK/STAT Signaling in Rheumatoid Arthritis and Osteoarthritis
por: Malemud, Charles J.
Publicado: (2017)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

Evolution of the JAK-STAT pathway
por: Liongue, Clifford, et al.
Publicado: (2013)

JAK-STAT signaling in stem cells and their niches in Drosophila
por: Bausek, Nina
Publicado: (2013)

Amygdalin promotes the activity of T cells to suppress the progression of HBV-related hepatocellular carcinoma via the JAK2/STAT3 signaling pathway
por: Wang, Ruoyu, et al.
Publicado: (2021)

Effects of JAK2-STAT3 signaling after cerebral insults
por: Raible, Daniel J, et al.
Publicado: (2014)

Ubiquitin-mediated regulation of JAK-STAT signaling in embryonic stem cells
por: Hatakeyama, Shigetsugu
Publicado: (2012)

The JAK-STAT pathway in hypertrophic stress signaling and genomic stress response
por: Wagner, Michael A., et al.
Publicado: (2012)

Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity
por: Wunderlich, Claudia M., et al.
Publicado: (2013)

Drosophila Jak/STAT Signaling: Regulation and Relevance in Human Cancer and Metastasis
por: Trivedi, Sunny, et al.
Publicado: (2018)

JAK/STAT Signaling and Cervical Cancer: From the Cell Surface to the Nucleus
por: Valle-Mendiola, Arturo, et al.
Publicado: (2023)

Association analyses of the JAK/STAT signaling pathway with the progression and prognosis of colon cancer
por: Tang, Shengbo, et al.
Publicado: (2019)

JAK/STAT signaling and human in vitro myogenesis
por: Trenerry, Marissa K, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_9kkgk1ar3k5krj21c6tndb1c6r